Compare Gitlab Inc (GTLB) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gitlab Inc vs Revvity Inc — how do they compare? Gitlab Inc trades at $31.64 (market cap $5.54B), while Revvity Inc trades at $110.75 (market cap $12.42B). The key difference: Revvity Inc is far larger — about 2.2× Gitlab Inc's market cap, and Revvity Inc pays a 0.25% dividend while Gitlab Inc pays none. Which is the better fit depends on your goals.
| GTLB | RVTY | |
|---|---|---|
Market Cap | $5.54B | $12.42B |
Sector | Technology | Technology |
52-Week High | $51.04 | $117.75 |
52-Week Low | $19.42 | $82.26 |
Enterprise Value | $4.29B | $14.91B |
Dividend Yield | — | 0.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GitLab (GTLB) trades at $32.98, down 1.46% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $32.50. The company reported strong revenue growth to $759 million in 2025, though it remains unprofitable with a net margin of -2.49%. Recent news highlights its leadership in DevSecOps and AI-driven software development, including a fourth consecutive Leader recognition in Gartner's Magic Quadrant as of June 2026.
Outlook: GitLab's strategic position in the AI and DevSecOps space offers growth potential, but high valuation multiples and persistent losses pose risks. Investor sentiment is mixed, with analysts divided between buy and hold ratings. Key catalysts include execution on profitability and enterprise adoption of AI tools, while competitive pressures and macroeconomic headwinds remain concerns.
RVTY trades at $110.99, down slightly by 0.2% today, near the analyst consensus price target of $111.43. The stock shows a bullish technical trend with recent earnings beats in Q3 2025, Q4 2025, and Q1 2026. Strong profitability metrics include a gross margin of 54.32% and net income margin of 8.26%. Recent news highlights AI integration advancements and FDA clearances, supporting growth prospects.
The outlook is positive with analyst consensus leaning buy (51.72%) and no sell ratings. Key risks include margin pressure and macroeconomic headwinds affecting cash flow, which turned negative in 2025 and 2026. The upcoming Q2 2026 earnings report on August 4, 2026, will be critical for validating current growth trajectory and investor confidence.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gitlab Inc
GitLab Inc operates on an all-remote model. The company is a technology company whose primary offering is GitLab, a complete DevOps platform delivered as a single application. GitLab is used by a wide range of organizations. The company also provides related training and professional services. GitLab is offered on both self-managed and software-as-a-service (SaaS) models. The principal markets for GitLab are currently located in the United States, Europe, and Asia Pacific. The company is focused on accelerating innovation and broadening the distribution of its platform to companies across the world.
Read more on GTLB →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
